Sesen Bio, Inc. (SESN), relating to its proposed merger with Carisma Therapeutics Inc. Under the terms of the agreement, SESN shareholders are expected to own approximately 41.7% of the combined company.
Sesen Bio, Inc. (SESN), relating to its proposed merger with Carisma Therapeutics Inc. Under the terms of the agreement, SESN shareholders are expected to own approximately 41.7% of the combined company.